JP Medical Consulting Pty Ltd (ACN 673 260 056, JP Medical) is pleased to announce the appointment of Ms. Nicoletta Muner as Senior Vice President, Global Regulatory Affairs.

Ms. Nicoletta Muner brings over 25 years of experience in the pharmaceutical industry, covering product development, preclinical and clinical development, and international regulatory affairs. She is the Founder and General Manager of Canary Regulatory Affairs, with exceptional expertise in global regulatory strategies across EMA, MHRA, FDA, and TGA. She has successfully registered a first-in-class orphan drug in the EU and US, and possesses extensive experience in regulatory submissions, clinical document development, and non-clinical study management.

Dr. James Pang, Chief Executive Officer of JP Medical, commented: “Nicoletta is a very senior with sophistically international experiences respected regulatory expert with deep knowledge across major regulatory markets. Her expertise will significantly strengthen our service capabilities and bring tremendous value to our clients. We are delighted to welcome her to the JP Medical network.”

JP Medical has established itself as a rapidly expanding service platform operating under its pioneering RCO + CRO business model. Through a group of independent companies working in collaboration, JP Medical provides full-suite solutions including ethics submissions, TGA CTN/CTX, clinical trial operation, regulatory support, medical and clinical affairs,  R&D rebates, and local sponsor services—for both Chinese pharmaceutical and biotech, and also for medical device companies in Australia to conduct clinical development in China.

Ms. Nicoletta Muner’s appointment further enhances JP Medical’s global regulatory expertise and reinforces its commitment to delivering high-quality services to its clients.